Abstract | INTRODUCTION: OBJECTIVE: METHODS: RESULTS: Twice a day weight based therapeutic regimen was applied for LMWH and activated partial thromboplastin time (aPTT) adjusted UFH dosages. After 2-6 weeks of antepartal deep vein thrombosis (DVT) treatment the dose of nadroparin was reduced to intermediate level. The duration of LMWH therapy during pregnancy was 1-35 weeks, on average 16 weeks. One case (0.62%) of DVT propagation into the vena cava occurred in a woman with antithrombin deficiency treated with LMWH. Two women (1.25%) had minor bleeding and 5 (3.125%) had minimal bleeding, while 3 (1.9%) had skin allergic reactions. The rate of successful pregnancy outcome was 97.2%. There were no cases of stillbirth or neonatal congenital abnormalities. Thrombophilia was found in 86 women (53.7%). No statistically significant correlation between the presence of thrombophilia and treatment complications were found. CONCLUSION:
Nadroparin is both safe and effective for the treatment of DVT during pregnancy and puerperium.
|
Authors | Gorana Mitić, Mirjana Kovac, Ljubica Povazan, Valentina Djordjević, Vesna Ilić, Iva Salatić, Radmila Lazić, Nebojsa Antonijević, Aleksandra Novakov-Mikić |
Journal | Srpski arhiv za celokupno lekarstvo
(Srp Arh Celok Lek)
Vol. 138 Suppl 1
Pg. 18-22
(Jan 2010)
ISSN: 0370-8179 [Print] Serbia |
PMID | 20229677
(Publication Type: Journal Article)
|
Chemical References |
- Anticoagulants
- Fibrinolytic Agents
- Nadroparin
- Heparin
|
Topics |
- Anticoagulants
(adverse effects, therapeutic use)
- Female
- Fibrinolytic Agents
(adverse effects, therapeutic use)
- Heparin
(adverse effects, therapeutic use)
- Humans
- Nadroparin
(adverse effects, therapeutic use)
- Pregnancy
- Pregnancy Complications, Cardiovascular
(drug therapy)
- Puerperal Disorders
(drug therapy)
- Venous Thromboembolism
(drug therapy)
|